Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Breast Cancer

  Free Subscription

Articles published in J Nucl Med

Retrieve available abstracts of 29 articles:
HTML format

Single Articles

    June 2020
  1. PETERSON LM, Kurland BF, Yan F, Novakova-Jiresova A, et al
    (18)F-Fluoroestradiol ((18)F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.244459. doi: 10.2967/jnumed.120.244459.
    PubMed     Abstract available

    March 2020
  2. ROUSSEAU C, Goldenberg DM, Colombie M, Sebille JC, et al
    Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer.
    J Nucl Med. 2020 Mar 13. pii: jnumed.119.236000. doi: 10.2967/jnumed.119.236000.
    PubMed     Abstract available

    January 2020
  3. LAFFON E, Marthan R
    SUVmax-V for assessing treatment response in FDG-PET Imaging of Patient-Derived Tumor Xenografts involving Triple-Negative Breast Cancer.
    J Nucl Med. 2020 Jan 10. pii: jnumed.120.241778. doi: 10.2967/jnumed.120.241778.

    December 2019
  4. HERNANDEZ R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, et al
    (177)Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.236265. doi: 10.2967/jnumed.119.236265.
    PubMed     Abstract available

  5. MCDONALD ES, Doot RK, Young AJ, Schubert EK, et al
    Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status.
    J Nucl Med. 2019 Dec 13. pii: jnumed.119.232363. doi: 10.2967/jnumed.119.232363.
    PubMed     Abstract available

    November 2019
  6. BIEGON A, Shroyer KR, Franceschi D, Dhawan J, et al
    Initial studies with [(11)C]vorozole positron emission tomography detect over-expression of intra-tumoral aromatase in breast cancer.
    J Nucl Med. 2019 Nov 22. pii: jnumed.119.231589. doi: 10.2967/jnumed.119.231589.
    PubMed     Abstract available

  7. SAVAIKAR MA, Whitehead T, Roy S, Strong L, et al
    SUV25 and microPERCIST: Precision Imaging of Response to Therapy in Co-Clinical FDG-PET Imaging of Triple Negative Breast Cancer (TNBC) Patient-Derived Tumor Xenografts (PDX).
    J Nucl Med. 2019 Nov 22. pii: jnumed.119.234286. doi: 10.2967/jnumed.119.234286.
    PubMed     Abstract available

  8. KUMAR M, Salem K, Tevaarwerk AJ, Strigel RM, et al
    Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.
    J Nucl Med. 2019 Nov 15. pii: jnumed.119.228858. doi: 10.2967/jnumed.119.228858.
    PubMed     Abstract available

    September 2019
  9. LEUNG CN, Canter BS, Rajon D, Back TA, et al
    Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with Radium-223: The Role of Bystander Effects and their Potential for Therapy.
    J Nucl Med. 2019 Sep 13. pii: jnumed.119.227835. doi: 10.2967/jnumed.119.227835.
    PubMed     Abstract available

  10. RAMOS N, Baquero J, Gironda Z, Zaim-Wadghiri Y, et al
    Non invasive PET imaging of CDK4/6 activation in Breast Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.232603. doi: 10.2967/jnumed.119.232603.
    PubMed     Abstract available

    June 2019
  11. LEITHNER D, Helbich TH, Bernard-Davila B, Marino MA, et al
    Multiparametric (18)F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?
    J Nucl Med. 2019 Jun 28. pii: jnumed.119.230003. doi: 10.2967/jnumed.119.230003.
    PubMed     Abstract available

    March 2019
  12. AZAD G, Siddique M, Taylor B, Green A, et al
    Reply to: Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with (18)F-fluoride.
    J Nucl Med. 2019 Mar 8. pii: jnumed.119.226555. doi: 10.2967/jnumed.119.226555.

  13. KUMAR M, Salem K, Michel CJ, Jeffery JJ, et al
    (18)F-Fluoroestradiol Positron Emission Tomography Imaging of Activating Estrogen Receptor Alpha Mutations in Breast Cancer.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224667. doi: 10.2967/jnumed.118.224667.
    PubMed     Abstract available

    February 2019
  14. LAFFON E, Marthan R
    Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with (18)F-fluoride.
    J Nucl Med. 2019 Feb 7. pii: jnumed.119.226092. doi: 10.2967/jnumed.119.226092.

    January 2019
  15. DOOT RK
    Practical methods for estimating metabolic flux (Ki) to assess response to therapy via static PET scans.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.220913. doi: 10.2967/jnumed.118.220913.

  16. MORTIMER JE, Shively JE
    Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA.
    J Nucl Med. 2019;60:23-25.

    September 2018
  17. ULANER GA, Juarez J, Riedl C, Goldman D, et al
    (18)F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men.
    J Nucl Med. 2018 Sep 20. pii: jnumed.118.217836. doi: 10.2967/jnumed.118.217836.
    PubMed     Abstract available

    July 2018
  18. AZAD G, Siddique MM, Taylor B, Green A, et al
    Does measurement of (18)F-fluoride metabolic flux improve response assessment of breast cancer bone metastases compared with standardised uptake values in (18)F-fluoride PET/CT?
    J Nucl Med. 2018 Jul 24. pii: jnumed.118.208710. doi: 10.2967/jnumed.118.208710.
    PubMed     Abstract available

  19. SALEM K, Kumar M, Yan Y, Jeffery JJ, et al
    Sensitivity and Isoform Specificity of (18)F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor Protein Response to Estradiol Challenge in Breast Cancer.
    J Nucl Med. 2018 Jul 20. pii: jnumed.118.211516. doi: 10.2967/jnumed.118.211516.
    PubMed     Abstract available

    June 2018
  20. KURLAND BF, Oesterreich S
    Heterogeneity in metastatic breast cancer (18)F-fluoroestradiol uptake - clinically actionable, biologically illuminating?
    J Nucl Med. 2018 Jun 14. pii: jnumed.118.214304. doi: 10.2967/jnumed.118.214304.

  21. SAH BR, Ghafoor S, Burger IA, Ter Voert EEGW, et al
    Feasibility of (18)F-FDG Dose Reductions in Breast Cancer PET/MRI.
    J Nucl Med. 2018 Jun 7. pii: jnumed.118.209007. doi: 10.2967/jnumed.118.209007.
    PubMed     Abstract available

    May 2018
  22. PETERSON LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, et al
    Prospective study of serial (18)F-FDG PET and (18)F-fluoride ((18)F-NaF) PET to predict time to skeletal related events, time-to-progression, and survival in patients with bone-dominant metastatic breast cancer.
    J Nucl Med. 2018 May 10. pii: jnumed.118.211102. doi: 10.2967/jnumed.118.211102.
    PubMed     Abstract available

    April 2018
  23. WU J, Wang S, Zhang X, Teng Z, et al
    (18)F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study.
    J Nucl Med. 2018 Apr 26. pii: jnumed.118.208637. doi: 10.2967/jnumed.118.208637.
    PubMed     Abstract available

    Now is the time to use FDG-PET/CT to optimize neoadjuvant treatment in triple negative breast cancer!
    J Nucl Med. 2018 Apr 19. pii: jnumed.118.210922. doi: 10.2967/jnumed.118.210922.

    March 2018
  25. NIENHUIS HH, van Kruchten M, Elias SG, Glaudemans AWJM, et al
    ((18))F-fluoroestradiol Tumor Uptake is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.198846. doi: 10.2967/jnumed.117.198846.
    PubMed     Abstract available

  26. MONTEMAGNO C, Bacot S, Ahmadi M, Kerfelec B, et al
    Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer.
    J Nucl Med. 2018 Mar 23. pii: jnumed.117.203489. doi: 10.2967/jnumed.117.203489.
    PubMed     Abstract available

    February 2018
  27. HUMBERT O, Lasserre M, Bertaut A, Fumoleau P, et al
    Pattern of breast cancer blood flow and metabolism, assessed using dual-acquisition (18)FDG PET: correlation with tumor phenotypic features and pathological response to neoadjuvant chemotherapy.
    J Nucl Med. 2018 Feb 9. pii: jnumed.117.203075. doi: 10.2967/jnumed.117.203075.
    PubMed     Abstract available

    November 2017
  28. ULANER GA, Lyashchenko SK, Riedl C, Ruan S, et al
    First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer.
    J Nucl Med. 2017 Nov 16. pii: jnumed.117.202010. doi: 10.2967/jnumed.117.202010.
    PubMed     Abstract available

    September 2017
  29. VENEMA CM, Mammatas LH, Schroder CP, van Kruchten M, et al
    Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies.
    J Nucl Med. 2017 Sep 14. pii: jnumed.117.193649. doi: 10.2967/jnumed.117.193649.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.